对乙酰氨基酚致药物性肝损伤的机制研究进展

余朋飞; 吴桥; 段钟平; 陈煜

doi:10.3969/j.issn.1001-5256.2019.09.050

对乙酰氨基酚致药物性肝损伤的机制研究进展

DOI: 10.3969/j.issn.1001-5256.2019.09.050

1. 首都医科大学附属北京佑安医院疑难肝病及人工肝中心肝衰竭与人工肝治疗研究北京市重点实验室
2. 首都医科大学附属北京天坛医院

基金项目:

国家重点研发计划资助(2017YFA0103000)；国家科技重大专项“艾滋病和病毒性肝炎等重大传染病防治”(2012ZX10002004-006,2017ZX10203201-005,2017ZX10201201-001-001,2017ZX10201201-002-002,2017ZX10202203-006-001,2017ZX10302201-004-002)；北京市医院管理局“登峰”人才培养计划基金资助项目(DFL20151601);北京市医院管理局临床医学发展专项经费资助(ZYLX201806)；

详细信息

中图分类号: R575
计量
- 文章访问数: 1877
- HTML全文浏览量: 103
- PDF下载量: 378
- 被引次数: 0
出版历程
- 收稿日期: 2019-05-13
- 出版日期: 2019-09-20

Research advances in the mechanism of drug-induced liver injury due to paracetamol

Difficult & Complicated Liver Diseases and Artificial Liver Center & Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing You An Hospital, Capital Medical University

Research funding:

摘要

摘要: 药物性肝病又称药物性肝损伤,是我国非感染性肝病的第二大病种,美国肝衰竭/肝移植的首要原因。药物性肝损伤主要分为固有型肝损伤和非特异质型肝损伤。固有型药物性肝损伤在临床前安全研究中是无法被预测到的,而大多数药物引起的非特异质型肝毒性在临床前研究中就会被发现从而不会被应用到临床,但其中一个例外就是对乙酰氨基酚(扑热息痛,APAP),这种药物在治疗剂量之内是安全的,但是过量服用则会导致严重的肝损伤甚至急性肝衰竭。在欧美等发达国家,APAP过量服用是导致急性肝衰竭的主要原因。因此进一步阐明APAP引起肝损伤的细胞和分子机制,尤其是肝细胞死亡的机制,有助于尽早识别发生急性肝衰竭和不良预后的危险因素,从而有针对性的开发阻断肝损伤进程的治疗靶点与方案。
- 醋氨酚 /
- 化学性与药物性肝损伤 /
- 细胞死亡 /
- 自噬
Abstract: Drug-induced liver disease, also known as drug-induced liver injury ( DILI) , is the second largest cause of non-infectious liver disease in China and the leading cause of liver failure or liver transplantation in the United States. DILI is classified into idiosyncratic and dose-dependent DILI. Idiosyncratic DILI is currently not predictable in preclinical safety studies, while dose-dependent hepatotoxicity due to most drugs can be identified in preclinical safety studies, and thus these drugs are not used in clinical practice. One notable exception is paracetamol ( APAP) , which is safe within therapeutic dose, but an overdose of this drug may cause severe liver injury and even acute liver failure. APAP overdose is the major cause of acute liver failure in developed countries in Europe and America. Therefore, further clarification of cellular and molecular mechanisms of DILI due to APAP, especially the mechanism of hepatocyte death, may help with the early identification of risk factors for acute liver failure and poor prognosis and the development of treatment targets and regimens to block the progression of liver injury.
- acetaminophen /
- chemical and drug induced liver injury /
- cell death /
- autophagy

HTML全文

参考文献(50)

[1] BHUSHAN B, APTE U. Liver regeneration after acetaminophen hepatotoxicity:Mechanisms and therapeutic opportunities[J].Am J Pathol, 2019, 189 (4) :719-729.

[2] SHEN T, HUANG X, WANG YY, et al. Current status of epidemiological study on drug-induced liver injury in China[J]. J Clin Hepatol, 2018, 34 (6) :1152-1155. (in Chinese) 沈弢, 黄昕, 王誉雅, 等.我国药物性肝损伤流行病学研究现状[J].临床肝胆病杂志, 2018, 34 (6) :1152-1155.

[3] IASELLA CJ, JOHNSON HJ, DUNN MA. Adverse drug reactions:Type A (intrinsic) or type B (idiosyncratic) [J]. Clin Liver Dis, 2017, 21 (1) :73-87.

[4] LEE WM. Acetaminophen (APAP) hepatotoxicity-Isn't it time for APAP to go away?[J]. J Hepatol, 2017, 67 (6) :1324-1331.

[5] JOZWIAK-BEBENISTA M, NOWAK JZ. Paracetamol:Mechanism of action, applications and safety concern[J]. Acta Pol Pharm, 2014, 71 (1) :11-23.

[6] DART RC, BAILEY E. Does therapeutic use of acetaminophen cause acute liver failure?[J]. Pharmacotherapy, 2007, 27 (9) :1219-1230.

[7] PEZZIA C, SANDERS C, WELCH S, et al. Psychosocial and behavioral factors in acetaminophen-related acute liver failure and liver injury[J]. J Psychosom Res, 2017, 101:51-57.

[8] MITCHELL JR, JOLLOW DJ, POTTER WZ, et al. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione[J]. J Pharmacol Exp Ther, 1973, 187 (1) :211-217.

[9] COEN M. Metabolic phenotyping applied to pre-clinical and clinical studies of acetaminophen metabolism and hepatotoxicity[J]. Drug Metab Rev, 2015, 47 (1) :29-44.

[10] SUBRAMANYA SB, VENKATARAMAN B, MEERAN MFN, et al. Therapeutic potential of plants and plant derived phytochemicals against acetaminophen-induced liver injury[J].Int Mol Sci, 2018, 19 (12) :67-71

[11] SAITO C, ZWINGMANN C, JAESCHKE H. Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine[J]. Hepatology, 2010, 51 (1) :246-254.

[12] ATHERSUCH TJ, ANTOINE DJ, BOOBIS AR, et al. Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions:A perspective[J]. Toxicol Res, 2018, 7 (3) :347-357.

[13] DUAN L, RAMACHANDRAN A, AKAKPO JY, et al. Role of extracellular vesicles in release of protein adducts after acetaminophen-induced liver injury in mice and humans[J].Toxicol Lett, 2019, 301 (1) :25-32.

[14] JAESCHKE H, MCGILL MR. Cytochrome P450-derived versus mitochondrial oxidant stress in acetaminophen hepatotoxicity[J]. Toxicol Lett, 2015, 235 (3) :216-217.

[15] BARBIER-TORRES L, IRUZUBIETA P, FERNANDEZ-RAMOS D, et al. The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury[J]. Nat Commun, 2017, 8 (1) :2068.

[16] JAESCHKE H, RAMACHANDRAN A. Oxidant stress and lipid peroxidation in acetaminophen hepatotoxicity[J]. React Oxyg Species, 2018, 5 (15) :145-158.

[17] JAESCHKE H. Acetaminophen:Dose-dependent drug hepatotoxicity and acute liver failure in patients[J]. Dig Dis, 2015, 33 (4) :464-471.

[18] MCGILL MR, JAESCHKE H. Metabolism and disposition of acetaminophen:Recent advances in relation to hepatotoxicity and diagnosis[J]. Pharm Res, 2013, 30 (9) :2174-2187.

[19] XIE Y, MCGILL MR, DU K, et al. Mitochondrial protein adducts formation and mitochondrial dysfunction during N-acetyl-m-aminophenol (AMAP) -induced hepatotoxicity in primary human hepatocytes[J]. Toxicol Appl Pharmacol, 2015, 289 (2) :213-222.

[20] YAN M, HUO Y, YIN S, et al. Mechanisms of acetaminophen-induced liver injury and its implications for therapeutic interventions[J]. Redox Biol, 2018, 17 (2) :74-83.

[21] RAMACHANDRAN A, JAESCHKE H. Mechanisms of acetaminophen hepatotoxicity and their translation to the human pathophysiology[J]. J Clin Transl Res, 2017, 3 (Suppl 1) :157-169.

[22] ZHANG J, MIN RWM, LE K, et al. The role of MAP2 kinases and p38 kinase in acute murine liver injury models[J]. Cell Death Dis, 2017, 8 (6) :e2903.

[23] ZAI W, CHEN W, LUAN J, et al. Dihydroquercetin ameliorated acetaminophen-induced hepatic cytotoxicity via activating JAK2/STAT3 pathway and autophagy[J]. Applied Microbiol Biotechnol, 2018, 102 (3) :1443-1453.

[24] ZHANG YF, HE W, ZHANG C, et al. Role of receptor interacting protein (RIP) 1 on apoptosis-inducing factor-mediated necroptosis during acetaminophen-evoked acute liver failure in mice[J]. Toxicol Lett, 2014, 225 (3) :445-453.

[25] SHAN S, SHEN Z, SONG F. Autophagy and acetaminophen-induced hepatotoxicity[J]. Arch Toxicol, 2018, 225 (3) :325-333.

[26] MIZUSHIMA N, KOMATSU M. Autophagy:Renovation of cells and tissues[J]. Cell, 2011, 147 (4) :728-741.

[27] NI HM, MCGILL MR, CHAO X, et al. Removal of acetaminophen protein adducts by autophagy protects against acetaminophen-induced liver injury in mice[J]. J Hepatol, 2016, 65 (2) :354-362.

[28] HAMACHER-BRADY A, BRADY NR. Mitophagy programs:Mechanisms and physiological implications of mitochondrial targeting by autophagy[J]. Cell Mol Life Sci, 2016, 73 (4) :775-795.

[29] WANG H, NI HM, CHAO X, et al. Double deletion of PINK1and Parkin impairs hepatic mitophagy and exacerbates acetaminophen-induced liver injury in mice[J]. Redox Biol, 2019, 22 (10) :1148.

[30] GAO Y, CHU S, ZHANG Z, et al. Early stage functions of mitochondrial autophagy and oxidative stress in acetaminophen-induced liver injury[J]. J Cell Biochem, 2017, 118 (10) :3130-3141.

[31] NI HM, BOCKUS A, BOGGESS N, et al. Activation of autophagy protects against acetaminophen-induced hepatotoxicity[J]. Hepatology, 2012, 55 (1) :222-232.

[32] YANG R, TONNESSEEN TI. DAMPs and sterile inflammation in drug hepatotoxicity[J]. Hepatology Int, 2019, 13 (1) :42-50.

[33] KUBES P, MEHAL WZ. Sterile inflammation in the liver[J].Gastroenterology, 2012, 143 (5) :1158-1172.

[34] ZHANG C, FENG J, DU J, et al. Macrophage-derived IL-1alpha promotes sterile inflammation in a mouse model of acetaminophen hepatotoxicity[J]. Cell Mol Immunol, 2018, 15 (11) :973-982.

[35] WOOLBRIGHT BL, JAESCHKE H. Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure[J]. J Hepatol, 2017, 66 (4) :836-848.

[36] WILLIAMS CD, FARHOOD A, JAESCHKE H. Role of caspase-1 and interleukin-1beta in acetaminophen-induced hepatic inflammation and liver injury[J]. Toxicol Appl Pharmacol, 2010, 247 (3) :169-178.

[37] WILLIAMS CD, ANTOINE DJ, SHAW PJ, et al. Role of the Nalp3inflammasome in acetaminophen-induced sterile inflammation and liver injury[J]. Toxicol Appl Pharmacol, 2011, 252 (3) :289-297.

[38] ALVARENGA DM, MATTOS MS, LOPES ME, et al. Paradoxical role of matrix metalloproteinases in liver injury and regeneration after sterile acute hepatic failure[J]. Cells, 2018, 7 (12) :211-220.

[39] WOOLBRIGHT BL, JAESCHKE H. Mechanisms of inflammatory liver injury and drug-induced hepatotoxicity[J]. Curr Pharmacol Rep, 2018, 4 (5) :346-357.

[40] WILLIAMS CD, BAJT ML, SHARPE MR, et al. Neutrophil activation during acetaminophen hepatotoxicity and repair in mice and humans[J]. Toxicol Appl Pharmacol, 2014, 275 (2) :122-133.

[41] BOURDI M, MASUBUCHI Y, REILLY TP, et al. Protection against acetaminophen-induced liver injury and lethality by interleukin 10:Role of inducible nitric oxide synthase[J].Hepatology, 2002, 35 (2) :289-298.

[42] TRIANTAFYLLOU E, WOOLLARD KJ, MCPHAIL MJW, et al.The role of monocytes and macrophages in acute and acuteon-chronic liver failure[J]. Front Immunol, 2018, 9:2948.

[43] ANTONIADES CG, QUAGLIA A, TAAMS LS, et al. Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans[J]. Hepatology, 2012, 56 (2) :735-746.

[44] MCGILL MR, YAN HM, RAMACHANDRAN A, et al. HepaRG cells:A human model to study mechanisms of acetaminophen hepatotoxicity[J]. Hepatology, 2011, 53 (3) :974-982.

[45] XIE Y, MCGILL MR, DORKO K, et al. Mechanisms of acetaminophen-induced cell death in primary human hepatocytes[J]. Toxicol Appl Pharmacol, 2014, 279 (3) :266-274.

[46] MCGILL MR, LEBOFSKY M, NORRIS HR, et al. Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment:Dose-response, mechanisms, and clinical implications[J]. Toxicol Appl Pharmacol, 2013, 269 (3) :240-249.

[47] MCGILL MR, WILLIAMS CD, XIE Y, et al. Acetaminopheninduced liver injury in rats and mice:Comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity[J]. Toxicol Appl Pharmacol, 2012, 264 (3) :387-394.

[48] HAN D, DARA L, WIN S, et al. Regulation of drug-induced liver injury by signal transduction pathways:Critical role of mitochondria[J]. Trends Pharmacol Sci, 2013, 34 (4) :243-253.

[49] MCGILL MR, STAGGS VS, SHARPE MR, et al. Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome[J]. Hepatology, 2014, 60 (4) :1336-1345.

[50] GENG WJ, LIU H, DING HG. Recent advances in drug-induced liver injury:Potential mechanisms, pathological features, and biomarkers[J]. J Clin Hepatol, 2019, 35 (4) :925-929. (in Chinese) 耿文静, 刘晖, 丁惠国.药物性肝损伤的潜在机制、病理特点及生物标志物[J].临床肝胆病杂志, 2019, 35 (4) :925-929.

施引文献

资源附件(0)

访问统计